Haojie Li

Summary

Affiliation: Harvard Medical School
Country: USA

Publications

  1. pmc A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 4:e103. 2007
  2. ncbi request reprint Prognostic factors in lymph node-positive prostate cancer
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Urology 67:1016-21. 2006
  3. ncbi request reprint Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
    Sven Perner
    Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:696-701. 2007
  4. pmc Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis
    Jing Ma
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Lancet Oncol 9:1039-47. 2008
  5. ncbi request reprint Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms
    Matthew H McIntyre
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 16:2233-6. 2007
  6. ncbi request reprint Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 65:2498-504. 2005
  7. pmc Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study
    Lorelei A Mucci
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Int J Cancer 125:1143-6. 2009
  8. pmc Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study
    Lorelei A Mucci
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 19:484-91. 2010
  9. ncbi request reprint Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Prostate 67:1354-61. 2007
  10. ncbi request reprint Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Room 452, 181 Longwood Avenue, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1557-61. 2005

Detail Information

Publications14

  1. pmc A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 4:e103. 2007
    ..Few studies have explored the joint association of circulating vitamin D levels with VDR polymorphisms...
  2. ncbi request reprint Prognostic factors in lymph node-positive prostate cancer
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Urology 67:1016-21. 2006
    ..The incidence of clinically localized PCa with concurrent lymph node metastasis has decreased to less than 1% in the United States but is between 10% and 15% in other countries...
  3. ncbi request reprint Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
    Sven Perner
    Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:696-701. 2007
    ..6-9.7, P < .001, respectively). In summary, PSMA is independently associated with PSA recurrence in a high-risk cohort and thus might provide insight into the additional use of adjuvant therapy. Validation on other cohorts is required...
  4. pmc Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis
    Jing Ma
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Lancet Oncol 9:1039-47. 2008
    ..We assessed the effect of prediagnostic BMI and plasma C-peptide concentration (reflecting insulin secretion) on prostate cancer-specific mortality after diagnosis...
  5. ncbi request reprint Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms
    Matthew H McIntyre
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 16:2233-6. 2007
    ..Experimental evidence has suggested that estrogen receptor alpha (coded by the gene ESR1) might increase prostate cancer risk, whereas estrogen receptor beta (coded by the gene ESR2) might reduce prostate cancer risk...
  6. ncbi request reprint Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 65:2498-504. 2005
    ..Both endogenous and exogenous antioxidants play an important and interdependent role in preventing clinically significant prostate cancer...
  7. pmc Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study
    Lorelei A Mucci
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Int J Cancer 125:1143-6. 2009
    ..However, our data indicate that prostate cancer cases who carry the variant N allele are more likely to be overweight, and may be more susceptible to the angiogenic influences of obesity in prostate cancer pathogenesis...
  8. pmc Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study
    Lorelei A Mucci
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 19:484-91. 2010
    ..Given the role of the IGF system in prostate cancer, ALS may influence carcinogenesis by modulating IGF-I levels or bioavailability...
  9. ncbi request reprint Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Prostate 67:1354-61. 2007
    ....
  10. ncbi request reprint Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Room 452, 181 Longwood Avenue, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1557-61. 2005
    ..Our results indicate that prediagnostic circulating VEGF levels are not associated with prostate cancer development and have limited value in predicting future risk of prostate cancer...
  11. ncbi request reprint A prospective study of plasma selenium levels and prostate cancer risk
    Haojie Li
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 96:696-703. 2004
    ..We examined the association between pre-diagnostic plasma selenium levels and risk of prostate cancer in men enrolled in the Physicians' Health Study...
  12. pmc Prospective study of plasma vitamin B6 and risk of colorectal cancer in men
    Jung Eun Lee
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:1197-202. 2009
    ..92 (0.55-1.56), 0.42 (0.23-0.75), and 0.49 (0.26-0.92; P(trend) = 0.01), respectively. In conclusion, vitamin B(6) may protect against colorectal cancer independent of other one-carbon metabolites and inflammatory biomarkers...
  13. ncbi request reprint The role of metastasis-associated protein 1 in prostate cancer progression
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer Res 64:825-9. 2004
    ..In summary, this study identified an association of MTA1 expression and prostate cancer progression...
  14. ncbi request reprint A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk
    Jorge E Chavarro
    Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 16:1364-70. 2007
    ..Animal models suggest that n-3 fatty acids inhibit prostate cancer proliferation, whereas n-6 fatty acids promote it, but epidemiologic studies do not uniformly support these findings...